diabetestalk.net

670g Medtronic

What It’s Like To Use The Medtronic 670g

What It’s Like To Use The Medtronic 670g

Jason Gensler, person with type 1 diabetes, is the founder of the Foundation for Type One Diabetes and the creator of the synergistic philanthropy model. He’s an out of the box thinker, beer aficionado, coffee connoisseur, and bacon fanatic. He proudly dedicates his life to social entrepreneurship on behalf of the global type 1 diabetes community. Jason is one of the first users of the Medtronic 670G hybrid closed loop insulin pump system, sometimes referred to as an artificial pancreas. He’s been wearing the pump for the last 23 months and is planning to help test the next iteration of Medtronic’s technology. He answered some questions for us about what it’s like to live with this promising new device. Tell us a bit about yourself and your experience with diabetes. How old were you when you were diagnosed with type 1 diabetes, and how did you manage your blood sugars before you started the 670G? I was diagnosed with T1D two weeks after my 16th birthday. My 17 year Dia-versary is on May 10th 2017. Prior to the 670G I was wearing the T-slim pump and using the Dexcom G4 CGM. I managed my BGs as best I could prior to the trial and although I could maintain about a 7.0% – 8.0% A1C it felt like a ton of work. What inspired you to sign up to try the 670G? I have participated in many trials over the last 5 years at the Barbara Davis Center, and have witnessed the progress being made in our industry. I went into the 670G pivotal trial with huge expectations, knowing what was on the line for the diabetes industry, our T1D community, and knowing how many companies are pursuing their own version of an artificial pancreas or ‘automated system’. I applaud Medtronic for their efforts to blaze the trail for the industry. In my opinion, they learned a great deal from the Continue reading >>

Insulin Pump System

Insulin Pump System

References * Mean Absolute Relative Difference. ** 3-4 calibrations per day required. 1. Bailey T, et al. Accuracy, Precision, and User Performance Evaluation of the CONTOUR®NEXT LINK 2.4 Blood Glucose Monitoring System. Poster presented at the 7th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD); 2014 February 5–8, Vienna, Austria. Important Safety Information: MiniMed® 670G System The Medtronic MiniMed 670G system is intended for continuous delivery of basal insulin (at user selectable rates) and administration of insulin boluses (in user selectable amounts) for the management of type 1 diabetes mellitus in persons, fourteen years of age and older, requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed 670G system includes SmartGuard technology, which can be programmed to automatically adjust delivery of basal insulin based on continuous glucose monitor sensor glucose values, and can suspend delivery of insulin when the sensor glucose value falls below or is predicted to fall below predefined threshold values. The system requires a prescription. The Guardian Sensor (3) glucose values are not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a fingerstick may be required. A confirmatory finger stick test via the CONTOUR®NEXT LINK 2.4 blood glucose meter is required prior to making adjustments to diabetes therapy. All therapy adjustments should be based on measurements obtained using the CONTOUR®NEXT LINK 2.4 blood glucose meter and not on values provided by the Guardian Sensor (3). Always check the pump display to ensure the glucose result shown agrees with the glucose results shown on the CONTOUR®NE Continue reading >>

Hybrid Closed Loop System.

Hybrid Closed Loop System.

NEW! The Suspend before low§ option avoids lows and rebound highs proactively by automatically stopping insulin 30 minutes before you reach your pre-selected low limits, then automatically restarts insulin when your levels recover, all without bothersome alerts. NEW! The Auto Mode‡ option automatically adjusts your basal insulin delivery every 5 minutes based on your sugar levels to keep you in target range, all day and night. Watch Video View Brochure Get Started NEW! Guardian® Sensor 3 continuous glucose monitoring sensor. Introducing the most accurate sensor from Medtronic, now with up to 7 day wear and easy insertion. It is the FIRST and ONLY continuous glucose monitoring sensor FDA approved and trusted to control insulin dosing. Exclusive CONTOUR®NEXT LINK 2.4 meter1 Get easy and accurate CGM calibration, insulin dosing and remote bolusing with our exclusive meter. “This device will mean peace of mind, in knowing a person will be in normal blood sugar range a great majority of the time,” “It’s a medical device with the potential to change the lives of more than 1 million Americans who suffer from Type 1 diabetes.” KEEP YOUR GLUCOSE IN RANGE SMARTGUARD® HCL TECHNOLOGY. Quick and easy access to your glucose and insulin information, all from the home screen. Bright color screen for easy readability - day or night. Waterproof - so you can enjoy underwater activities. Quick and easy bolus from your meter. Fewer shots than multiple daily injections. The only sensor FDA approved and trusted to control insulin dosing. Easy to insert. Know at all times where your glucose levels are trending. Click here for assistance if your insurance does not currently cover the MiniMed 670G system. * Mean Absolute Relative Difference. ** 3-4 calibrations per day required. Continue reading >>

Why I Won't Be Switching To Medtronic's 670g Insulin Delivery System Billed As The First Artificial Pancreas - Medcity News

Why I Won't Be Switching To Medtronic's 670g Insulin Delivery System Billed As The First Artificial Pancreas - Medcity News

5 Comments / Feb 26, 2018 at 5:32 PM When Medtronic won approval for the MiniMed 670G from the FDA in 2016 , it was a big deal. Advertised as The Worlds First Hybrid Closed Loop System, it is the first commercial product of its kind able to automate insulin delivery and requiring lesser patient input than in the past. However, after reading more about the specifics, and having heard more first-hand accounts, I can now safely say that I am somewhat underwhelmed. When evaluating the 670G I was exclusively looking at the features of the auto mode in comparison to the system I use now. That is the OpenAPS, which is an open source artificial pancreas solution built using an Intel Edison (tiny computer) and a Medtronic insulin pump. My initial thought was that it might be nice to use a commercial solution instead of an open source one if it could make my daily life easier (there are elements of using an open source solution that are tiring at best). Here I lay out the reasons that drove my decision to stick with what I have instead of switching to Medtronics CGM. It should be noted, however, there is no one-size-fits-all solution for insulin-dependent diabetics. Ultimately, its a personal choice. What its really doing, not just what the basal rate has been adjusted to, but how the system got to that decision. Its not that I always read the exact calculations of the OpenAPS algorithm, but I could because I can access my live information at any time. I can access not just my blood glucose (BG) and basal insulin rate, but also the actual numbers and calculations going into the recommendations and changes that the system is making. No personalized targets for blood glucose levels The system targets 120 all of the time. The only other option is a temp target of 150 meant for exer Continue reading >>

Medtronic Launches Minimed 670g In The United States

Medtronic Launches Minimed 670g In The United States

Breakthrough in diabetes management took strong partnerships and willing trial participants. html5: Unsupported video format. Try installing Adobe Flash. The cellphone of an average teenager is a flurry of sent and received text messages. But there is one text message in particular that 16-year old Tia Geri will remember for a long time. “I was between classes and my mom texted me,” she recalls. “I was like – no way.” That text contained a word that could someday be a difference maker for millions of people living with type-1 diabetes. “Approved.” “I was so excited,” says Tia. “This was approved months before anyone thought it would be.” Just 104 days after submission by Medtronic, the U.S. Food and Drug Administration approved what many in the industry were calling “a breakthrough in diabetes management” – the Medtronic MiniMed 670G. Launched commercially in the United States on June 7, 2017 and available to patients 14 and older, it’s the world’s first hybrid closed-loop system and the most advanced insulin pump and sensor to date. Very few teenagers get excited about news from the FDA, but Tia isn’t your average teenager. She participated in the MiniMed 670G clinical trial. “It’s fun using the cutting-edge technology,” she says. “I love doing clinical trials, studies, giving feedback, and making devices safe for people in the future.” She called the MiniMed 670G a “life-changer.” And that kind of reaction was likely one of the reasons why the system gained FDA approval much earlier than expected. “It’s the culmination of years of hard work,” says Alejandro Galindo, president of Intense Insulin Management for the Diabetes Group at Medtronic. “The speed by which the FDA approved our application is truly unpreceden Continue reading >>

Different Reviews: Medtronic 670g | Integrated Diabetes Services

Different Reviews: Medtronic 670g | Integrated Diabetes Services

Several months ago, Gary posted his thoughts after trying out the Medtronic 670G hybrid closed loop system . Since then, two other IDS clinicians have given the system a try: Both have extensive experience using a variety of insulin pumps and CGM devices. After several months of using the 670G in auto-mode, in which the pump self-adjusts basal insulin delivery based on input from Medtronics Guardian continuous glucose monitor, heres what they had to say. Q: What were your needs/expectations going into using 670G? I was optimistic about trying the 670G. I wanted it to make life with diabetes easier as well as safer all around. Given it is the only FDA approved hybrid loop system on the market, it opens the doors for this type of technology to get approved from other pump companies as well. This is very exciting since we all need a partner so to speak in our self-management. Up to this point, all the pumps on the market have had smart features, but the PWD is the one who has to make use of the smart features by using their own brain to enable them. With the variables we each have in our day to day lives, this means constant interaction if we really want to avoid a roller coaster. Having type 1 for almost 30 years now, Ive managed to figure out adjustments to many of the variables that affect my management. But, I would really like a product that has my back a partner in this 24/7 of management. Essentially, one that can fill in the gaps between the times that Im not looking at my CGM screen or checking my BG. With 2 kids now (5 years old and 14 months old), that tends to be less often the looking and evaluating for making changes now, and more the oh, I think I see a pattern here, but Ill have to make an adjustment when my son doesnt have glue all over the kitchen table, Continue reading >>

Medtronic Minimed® 670g Insulin Pump System

Medtronic Minimed® 670g Insulin Pump System

The MiniMed® 670G Insulin Pump System is the first hybrid closed loop (HCL) system. This system offers the most advanced SmartGuard® HCL technology, with two new levels of personalization. Manual Mode with the Suspend Before Low feature automatically stops insulin 30 minutes before pre-selected low limits, then restarts once insulin levels recover. Auto Mode continuously reads sensor glucose values and automatically adjusts basal insulin every 5 minutes. Guardian Sensor® 3 provides up to 7 days of wear Waterproof design with user-friendly color screen and simple menu Built-in CGM allows for wireless transmittal of glucose information every five minutes Bolus Wizard® makes it easier to calculate mealtime insulin and may avoid insulin stacking CCS Medical offers Ascensia Diabetes Care strips for use with Medtronic pumps for many insurance plans. Continue reading >>

Medtronic Minimed 670g System Review

Medtronic Minimed 670g System Review

After months of waiting, I finally received the world’s first hybrid closed loop system, the Minimed 670G system. Medtronic’s Minimed 670G system is an insulin pump and continuous glucose monitor that also has technology to put you in “auto” mode where it will automatically adjust your basal insulin every 5 minutes based on your blood sugar levels. I’ve had the system for about two weeks now so I thought I’d share my thoughts on it. I’m going to break this down into two posts because I feel the auto mode review needs it’s on page. I’ve been with Medtronic and on an insulin pump since 1997, 20 years! For most of the 20 years, the insulin pump has looked the exact same. It has “mainly” had the same features and not a lot of technology advancements. This new pump, however, is completely different than anything Medtronic has released in the last 20 years, with one caveat that they did release the Minimed 630G a few months prior. I received the Minimed 630G as part of the Minimed 670G Priority Access Group. In case you weren’t aware, Medtronic released a new pump, the 630G, last year and a few weeks (or months, not positive on the timing), the FDA approved their 670G pump faster than they realized. To not waste all the millions of dollars they probably spent on the 630G, they started a Priority Access Group for the 670G where you had to get the 630G first and then once the 670G was released, you could be the first to get it. The stars aligned for me where my pump went out of warranty last year and I had reached my out of pocket max because of the birth of my baby, so I was able to get the 630G for free! I never did use the 630G though because the new design of the pump sort of scared me and I was happy with my old pump. Because I never used the 630G, Continue reading >>

Minimed 670g System - P160017/s017

Minimed 670g System - P160017/s017

This is a brief overview of information related to FDA's approval to market this product. See the links below to the Summary of Safety and Effectiveness Data (SSED) and product labeling for more complete information on this product, its indications for use, and the basis for the FDA's approval. Address: 18000 Devonshire Street, Northridge, CA, 91325 What is it? The MiniMed 670G System is a hybrid closed loop system that monitors glucose and automatically adjusts the delivery of long acting or basal insulin based on the user's glucose reading. This device was approved on September 28, 2016 under P160017. The current approval adds a new indication to insert the sensor into the patient's upper arm. How does it work? The MiniMed 670G System consists of a continuous glucose monitor (CGM) that measures the user's glucose levels for up to seven days, an insulin pump that delivers insulin to the user, and a glucose meter used to calibrate the CGM. The MiniMed 670G System is able to decrease or stop insulin delivery when it detects the user's glucose is low, or increase the insulin delivery when the system detects the user's glucose levels are high with no input from the user. The glucose sensor contains a wire that is inserted under the skin on the abdomen or, as approved in this supplement, the upper arm. The glucose sensor measures glucose values in the tissue fluid. The glucose values are wirelessly sent to the insulin pump, and displayed along with glucose trend information, alerts, and alarms on the pump screen. The insulin pump delivers a prescribed dosage of insulin through an infusion set. The insulin pump can automatically adjust the delivery of insulin using a mathematical equation, or algorithm that incorporates information from the CGM. The system has two modes; Ma Continue reading >>

Medtronic 670g Hybrid Closed-loop System Launches For Select Priority Access Users

Medtronic 670g Hybrid Closed-loop System Launches For Select Priority Access Users

Medtronic has been busy since their unexpected FDA approval of their Minimed 670G Hybrid Closed-Loop system in October of last year, so quickly after receiving approval for the 630G in August. And now, after many months of preparing their teams for the launch, they are looking to begin to go live! I was able to speak with Mike Hill, VP of Global Communications, and Karrie Hawbaker, Senior Social Media manager, last week to get insight into their plan for the launch of the Minimed 670G. Initial Limited Launch This week begins customer training phase with small group of priority access program participants who have insurance coverage under their existing policies.Users will be given access to a team specially trained and dedicated to help them get accustomed to the new 670G Hybrid Closed-Loop system through their Start Right Program. During this time, they will be “validating robust customer service and onboarding experience with select number of provider sites. They’ll be bringing on a small, diverse amount of provider sites that will also bring a diverse base of patients: Large providers, small providers, CGM experience/ no CGM experience, different geographies and backgrounds, so that for all of those types of scenarios, they’ve validated their training material, onboarding protocols, and help lines to ensure that everything is up and running in the best possible way for those selected users.” They are expecting to fully launch the Minimed 670G Hybrid Closed-Loop system in June: first to the remaining users who have signed up for the Priority Access Program, and then to others who are interested in upgrading. Mike says: “The key goal for us through these different phases are to ensure an optimal experience so every patient who is making a decision to transiti Continue reading >>

Medtronics Minimed 670g Review | Worlds First

Medtronics Minimed 670g Review | Worlds First "artificial Pancreas - Dlife

Review: Worlds First Artificial Pancreas, Medtronics MiniMed 670G System Its almost been a year since the worlds first artificial pancreas, Medtronics MiniMed670G System has been commercially available. The device is theonly approved insulin pump that automatically delivers basal insulin to control blood glucose levels in the world. We review the MiniMed670G system with renown diabetes expert, Dr. DavidKlonoff, medical director of the Diabetes Research Institute, Mills-Peninsula Medical Center in San Mateo, Calif., to learn more about the device. Heres what we found out: The main features of the 670G system are three components manufactured by Medtronic: These include a CGM, a pump, and a dedicated algorithm that sets a target glucose level of 120 mg/dl, almost all of the time. The device features the companys most advanced algorithm SmartGuard(TM) HCL the latest innovation in Medtronics phased approach toward developing a fully automated, closed-loop system, according to the company press release. It is a unique product that can deliver hybrid closed-loop control to manage diabetes, Klonoff says, this degree control of glucose levels between meals is a breakthrough in treating diabetes. The system also provides a manual mode of control with options to program insulin suspension for either a fall in the glucose level down to a low glucose threshold or for a predicted impending low glucose level. However, Klonoff notes the system components cannot be swapped out with components made by another manufacturer. If a patient insists on using a CGM, a pump or an algorithm developed by another manufacturer, then they cannot use the 670G because the 670G contains a specific set of products made by Medtronic, he points out. Technology breeds competition, says Klonoff. I expect t Continue reading >>

A Nurses Review: Medtronic 670g Insulin Pump

A Nurses Review: Medtronic 670g Insulin Pump

Medtronic’s 670 G hybrid closed loop system is the smartest insulin pump to hit the market, and people living with type 1 diabetes, including my daughter and I, have been gobbling them up. As we embark into our second week on this new system, the majority of the time I’m all in, thinking: “This is amazing, I haven’t drank juice in days,” “I need to eat something – just to eat, not because I need to balance my diabetes,” “It’s so nice not to have T1D awaken me from sleep,” or “I feel less worried about my daughter.” All remarkable thoughts. A minority of the time, I’m thinking: “Why is this pump buzzing at me again?” “This algorithm isn’t really getting me into the 120 range,” “This sensor is frustrating – my Dexcom was so simplistic to use compared to this finicky Guardian 3 sensor,” “I wish I could calibrate anytime; there’s so much button pushing and user demand.” It’s not all peaches and cream – it’s a work in progress. Patience, I tell myself. It will get to know me better. Most people report that it takes a month to love the Medtronic 670G. Truth be told: I’m one week in, and I do love it 90% of the time – as does my 15 year old. Getting Started on the 670G We personally utilized the “Pathway Program” Medtronic offered through the end of April, 2017, placing us in a virtual line for the Medtronic 670G upgrade. We were fortunate enough to have purchased our pumps less than a year prior, so our out of pocket was expensive, but not unthinkable. Word has it that 50,000 customers have ordered the Medtronic 670G pump, but customers have faced hurdles along the way with the age of their current pumps and/or lack of insurance coverage for a new pump. Owning a pump that isn’t out of warranty means we’re at Continue reading >>

670g And Me: Insights And Incites On Medtronic’s Latest System

670g And Me: Insights And Incites On Medtronic’s Latest System

What’s the purpose of a diabetes management device? Is it to lower A1c? Prevent hypoglycemia? Spend more time in-range? Some combination of all three? Or perhaps we have to look beyond blood sugar control. After all, quality of life has to count for something. Does it make living with diabetes safer and easier? My Detailed Review of The MiniMed 670G from Medtronic The MiniMed 670G from Medtronic is an insulin pump coupled with a glucose sensor. It uses a computer program (called an “algorithm”) to automate certain aspects of insulin delivery. I decided to try 670G partially out of professional interest (everybody and their great aunt has been asking for my opinion on the system), and partially out of personal interest, as my blood glucose control hasn’t been the greatest the past couple of years. Let me start out by saying this: Since I started using 670G, my overall blood glucose control is better. I have to keep reminding myself of this non-consequential fact, because every day I find things about this system that I don’t particularly like. In my opinion, the pump itself leaves a lot to be desired. There are so many features and so many menus and so many safety/confirmation steps that my button thumb is starting to form a blister. The color screen is nice, but not large enough to display everything it needs to display. And the freakin’ clip is upside down. The reservoir connector pokes me in the gut every time I bend over, and I have to unclip it to see the screen and programming menus in the proper orientation. The “hybrid closed loop” part of the system (what I prefer to call the “semi-automatic feature”) is what makes 670G special. It functions by making adjustments to the BASAL insulin based on data received from the linked glucose sensor. Sinc Continue reading >>

Getting Personal With Medtronic's Minimed 670g

Getting Personal With Medtronic's Minimed 670g

Today, we welcome back Wil Dubois with the second part of his product review of the new Medtronic Minimed 670G, also known as the first Hybrid Closed Loop system ever approved worldwide. This advanced insulin pump-CGM combo received regulatory approval a year ago in September 2016 and has been slowly launching in the U.S. over the past several months. Wil offered his first impressions of the 670G earlier his summer, and has now been on the system long enough to share the Quality of Life impacts he's experienced. Test-Driving the Minimed 670G: Part Two As I boxed up my Medtronic 670G at the end of my three-month trial, a wave of relief swept over me. This took me by surprise, as I’ve always been a pump lover and had been chomping at the bit to try this new device -- the pinnacle of all that we tech-savvy T1s have been clamoring for -- since I'd first read about it. But in the course of using it, I experienced a shift not only in how I felt about the 670G, but about the invasiveness of insulin pumps in general for the first time ever. To dig into the story of what happened, we have to start at the very beginning with a refresher on the system basics. Medtronic 670G Basics Officially known as a "Hybrid Closed Loop" because it only does some of the diabetes thinking for you and leaves the rest in the user's hands, the 670G is the first of its kind and is by most accounts an early generation of an Artificial Pancreas system. It has three modes: Auto, Safe, and Manual. Manual mode: In this mode, the 670G functions as pretty much a garden-variety pump, albeit a nice one. It uses basal rates set by the user and his or her medical team, has variable insulin-to-carb ratios and correction factors, allows for dual and square wave boli and temporary basal rates, and has a low susp Continue reading >>

Medtronic Minimed 670g Help For Diabetics Needing Insulin

Medtronic Minimed 670g Help For Diabetics Needing Insulin

There are an estimated 86 million diabetics in the U.S. Of those, about 3 million have Type I Diabetes, a disease in which the body produces none of its own insulin. And millions of the Type II diabetics are on a full-insulin replacement. They spend countless hours injecting themselves and pricking their fingers to check their blood sugar, often chasing what can seem like an endless loop of highs and lows. Now theres at least a partial solution. Officially, its the Medtronic MiniMed 670G . Unofficially its been called the artificial pancreas (a name the American Diabetes Association and Medtronic would prefer you didnt use since it overstates the systems capabilities). Medtronic bills it as the worlds first hybrid closed loopsystem; the first [and so far only FDA approved] system that constantly self-adjusts to automatically keep glucose levels in target range. The two major components of the MiniMed System, the insulin pump and thecontinuous glucose monitor (CGM) are not new. The first wearable insulin pump was invented by Dean Kamen back in 1973 and came to market three years later. The first practical CGM came from MiniMed (later purchased by Medtronic) in 1999. So why has it taken so long to get these two devices to work with each other? The short answer is technology. Putting the two of them together required the development of complex algorithms that just didnt exist before, and a microprocessor-based platform capable of making the connection. You can read some of the development history here . First approved by the FDA in the fall of 2016, Medtronic brought it to market in spring of 2017. The launch has been so successful it has brought on growing pains for the company in terms of production and customer service (more on that later). It was aimed at Type I diabe Continue reading >>

More in diabetes